Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Large submacular hemorrhages after verteporfin therapy.
Do DV, Bressler NM, Bressler SB. Do DV, et al. Among authors: bressler nm, bressler sb. Am J Ophthalmol. 2004 Mar;137(3):558-60. doi: 10.1016/j.ajo.2003.08.001. Am J Ophthalmol. 2004. PMID: 15013883
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.
Saperstein DA, Rosenfeld PJ, Bressler NM, Rosa RH Jr, Sickenberg M, Sternberg P Jr, Aaberg TM Sr, Aaberg TM Jr, Reaves TA; Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Saperstein DA, et al. Among authors: bressler nm. Ophthalmology. 2002 Aug;109(8):1499-505. doi: 10.1016/s0161-6420(02)01103-x. Ophthalmology. 2002. PMID: 12153802 Clinical Trial.
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Blumenkranz MS, et al. Among authors: bressler nm, bressler sb. Arch Ophthalmol. 2002 Oct;120(10):1307-14. doi: 10.1001/archopht.120.10.1307. Arch Ophthalmol. 2002. PMID: 12365909 Clinical Trial.
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Bressler NM, et al. Among authors: bressler sb. Arch Ophthalmol. 2002 Nov;120(11):1443-54. doi: 10.1001/archopht.120.11.1443. Arch Ophthalmol. 2002. PMID: 12427056 Clinical Trial.
Improvement after verteporfin therapy.
Anand R, Bressler NM, Bressler SB, Gray TE, Harvey P, Haynes L, Koester JM, Manos KS, Miller JW, Murphy S, Reaves A, Sickenberg M, Singerman LJ, Strong A, Stur M; "Improvement After Verteporfin Therapy" Writting Committee for TAP Study Group. Anand R, et al. Among authors: bressler nm, bressler sb. Arch Ophthalmol. 2003 Mar;121(3):415-6. doi: 10.1001/archopht.121.3.415. Arch Ophthalmol. 2003. PMID: 12617718 No abstract available.
429 results